Revolution Medicines, Inc. provided earnings guidance for the full year 2022. For the period, the company projected GAAP net loss to be between $260 million and $280 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
37.63 USD | +1.43% | -3.90% | +30.75% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+30.75% | 6.12B | |
+34.67% | 52.85B | |
-7.36% | 38.87B | |
+34.86% | 38.24B | |
-11.12% | 26.79B | |
+11.74% | 26.16B | |
-19.86% | 19.9B | |
+39.01% | 13.18B | |
+30.31% | 12.24B | |
-3.41% | 11.79B |
- Stock Market
- Equities
- RVMD Stock
- News Revolution Medicines, Inc.
- Revolution Medicines, Inc. Provides Earnings Guidance for the Full Year 2022